文献速递肿瘤 PET/CT

[68Ga]Ga-anti-CD206-sdAb用于PET/CT评估实体瘤中促肿瘤巨噬细胞存在的Ⅰ期研究(MMR Ⅰ期)

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
PubMed 文献 · J Nucl Med · 2023-07-20

这是一项首次人体Ⅰ期研究,纳入7例实体瘤患者,主要评价[68Ga]Ga-NOTA-anti-CD206-sdAb的安全性、生物分布与剂量学,次要评价肿瘤摄取。结果显示该示踪剂安全耐受、血液清除快、经肾排泄,注射后90分钟可获得高对比噪声比图像,辐射剂量与常规PET示踪剂相当。

要点

  • [68Ga]Ga-NOTA-anti-CD206-sdAb安全且耐受良好,仅1例出现可能与研究药物相关的轻度短暂头痛。
  • 血液清除快,注射后80分钟剩余活度不足20%,注射后90分钟可获得高对比噪声比图像。
  • 初步数据显示3例后续进展患者的肿瘤摄取高于3例无进展患者,另1例因技术故障无法评价。

核心结论

  • [68Ga]Ga-NOTA-anti-CD206-sdAb安全且耐受良好,血液清除快并经肾排泄,注射后90分钟可实现高对比噪声比成像。
  • 该示踪剂辐射剂量与常规使用的PET示踪剂相当,上述发现及癌症患者的初步结果值得在Ⅱ期临床试验中进一步研究。

研究设计与样本

  • 首次人体Ⅰ期研究,纳入7例肿瘤至少10 mm、美国东部肿瘤协作组评分为0或1、肾功能和肝功能良好的实体瘤患者。
  • 主要目标为评价示踪剂的安全性、生物分布与剂量学,次要目标为评估肿瘤摄取。
  • 安全性通过注射前后临床检查与采血评价;注射后11、90、150分钟行PET/CT以评估生物分布与剂量学,并在选定时间点采血评估血液清除及血、尿代谢物。

主要发现

  • 7例患者平均注射191 MBq的[68Ga]Ga-NOTA-anti-CD206-sdAb,仅1例出现可能与研究药物相关的轻度短暂不良事件(头痛,常见不良事件评价标准1级)。
  • 血液清除快,注射后80分钟剩余活度不足20%;肝、肾、脾、肾上腺及红骨髓可见摄取;未检测到代谢物。
  • 放射性药物的平均有效剂量男性为4.2 mSv、女性为5.2 mSv。
  • 肿瘤摄取初步数据显示,3例后续进展患者的摄取高于3例无进展患者;1例因技术故障无法评价。

局限性

  • 肿瘤摄取为初步数据,仅3例后续进展患者与3例无进展患者可比,另1例因技术故障无法评价。
  • 原文结论指出上述发现及癌症患者的初步结果值得在Ⅱ期临床试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Macrophages play an important role throughout the body. Antiinflammatory macrophages expressing the macrophage mannose receptor (MMR, CD206) are involved in disease development, ranging from oncology to atherosclerosis and rheumatoid arthritis. [68Ga]Ga-NOTA-anti-CD206 single-domain antibody (sdAb) is a PET tracer targeting CD206. This first-in-human study, as its primary objective, evaluated the safety, biodistribution, and dosimetry of this tracer. The secondary objective was to assess its tumor uptake. Methods: Seven patients with a solid tumor of at least 10 mm, an Eastern Cooperative Oncology Group score of 0 or 1, and good renal and hepatic function were included. Safety was evaluated using clinical examination and blood sampling before and after injection. For biodistribution and dosimetry, PET/CT was performed at 11, 90, and 150 min after injection; organs showing tracer uptake were delineated, and dosimetry was evaluated. Blood samples were obtained at selected time points for blood clearance. Metabolites in blood and urine were assessed. Results: Seven patients were injected with, on average, 191 MBq of [68Ga]Ga-NOTA-anti-CD206-sdAb. Only 1 transient adverse event of mild severity was considered to be possibly, although unlikely, related to the study drug (headache, Common Terminology Criteria for Adverse Events grade 1). The blood clearance was fast, with less than 20% of the injected activity remaining after 80 min. There was uptake in the liver, kidneys, spleen, adrenals, and red bone marrow. The average effective dose from the radiopharmaceutical was 4.2 mSv for males and 5.2 mSv for females. No metabolites were detected. Preliminary data of tumor uptake in cancer lesions showed higher uptake in the 3 patients who subsequently progressed than in the 3 patients without progression. One patient could not be evaluated because of technical failure. Conclusion: [68Ga]Ga-NOTA-anti-CD206-sdAb is safe and well tolerated. It shows rapid blood clearance and renal excretion, enabling high contrast-to-noise imaging at 90 min after injection. The radiation dose is comparable to that of routinely used PET tracers. These findings and the preliminary results in cancer patients warrant further investigation of this tracer in phase II clinical trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gondry O, Xavier C, Raes L, et al. Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I). J Nucl Med. 2023. PMID: 37474271. doi:10.2967/jnumed.122.264853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。